Please login to the form below

Not currently logged in
Email:
Password:

Dr Robert Kim joins Apellis as chief medical officer

Brings experience from Novartis, Genentech and GSK

Apellis Pharmaceuticals Dr Robert KimDr Robert Kim has taken up a role at Apellis Pharmaceuticals as chief medical officer, bringing to the US clinical stage immunotherapy company experience from Novartis, Genentech and GSK.

While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.

Meanwhile, at he served at GSK as VP of clinical ophthalmology, helping build its early stage clinical pipeline, and was VP and head of pharmaceutical product development at Novartis/Alcon.

Most recently he was at retina startup Vision Medicines, where he was chief medical officer and head of R&D.

In his new role at Louisville, Kentucky-based Apellis Dr Kim will help the company optimise its drug development strategy as its clinical programmes progress toward late-stage clinical testing.

Apellis CEO Cedric Francois said: "Bob is an experienced clinical drug developer whose deep knowledge and experience will help us prepare for our confirmatory trials in geography atrophy and the further expansion of our exciting clinical pipeline centred on the inhibition of complement factor C3."

11th August 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics